Octapharma Group reports strong results for 2018

Reporting revenue of €1.8 billion and operating income of €346 millionGroup sales increased 4.5% com...

Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies

Lachen, Switzerland – 26 November 2018 – Octapharma today announced that the Swiss Agency for Therap...


Octapharma’s success is the result of the combined contribution of all employees, what we call “the human factor”. To embark on a challenging and rewarding career in an innovative biopharmaceutical organization, explore our global opportunities 

Annual Report 2018

Online Version